FromBio Hits Limit-Up as Trading Resumes; Curacle Surges on Follow-On Licensing Hopes [K-Bio
South Korean biotech stocks rose as the KOSDAQ rebounded. FromBio surged to the daily upper limit after trading resumed following a 5-for-1 reverse stock split, closing at 3,330 won (+29.82%). It reported 72.2b won revenue in 2025 and an 18.6b won operating loss. Curacle jumped over 18% on hopes of follow-on licensing after its $1.08b MT-103 deal.
How this was made
The 30-second read
Why it matters
FromBio’s immediate tradability catalyst produced a limit-up print, but the text emphasizes ongoing operating losses and leverage. Curacle’s move is driven by broker-identified follow-on assets (MT-101, CU01) and conditional upside tied to MT-103 Phase 1 data.
Market read
Traders can act on same-session catalysts: FromBio’s reverse-split trading resumption and Curacle’s licensing optionality narrative tied to broker-flagged follow-on assets.
What to watch
For FromBio, the article’s balance-sheet stress (high current liabilities and short-term borrowings vs low cash) could cap upside even with improved trading dynamics; for Curacle, Tie2 agonist history of pipeline removals (Roche, Astellas) raises the probability of clinical setbacks.
Background
The article frames a KOSDAQ rebound and highlights two biotech-specific catalysts: FromBio’s trading resumption after a 5-for-1 reverse split, and Curacle’s rally on licensing follow-on expectations after its MT-103 deal.
Ticker impact
FromBio resumed trading after a 5-for-1 reverse stock split and hit the KOSDAQ daily upper limit, with investors focused on the “second phase of growth.”
Expect elevated volatility and follow-through attempts on any additional financing or profitability milestones; downside risk if debt/cash dynamics worsen.
The article provides a concrete catalyst (trading resumption after reverse split) and a quantified financial snapshot (current assets vs liabilities, cash vs short-term borrowings), which frames both upside momentum and balance-sheet risk.
Market effects
KOSDAQ biotech sentiment may strengthen for licensing-driven platforms, especially retinal and vascular endothelial dysfunction programs.
Supports a broader rebound in South Korean pharma and biotech as the KOSDAQ recovered.
Limited direct global spillover, but licensing-deal narratives can influence how investors price early-stage biotech pipelines internationally.
Counterpoint
Limit-up and double-digit jumps may fade if the reverse-split “second phase” lacks near-term balance-sheet relief or if follow-on licensing remains speculative until clinical milestones.
Key entities
- companyFromBio
KOSDAQ-listed biotech that resumed trading after a 5-for-1 reverse stock split and hit the daily upper limit; still shows operating losses and high short-term borrowings.
- companyCuracle
KOSDAQ-listed biotech that jumped over 18% on expectations of additional licensing deals after its $1.08B MT-103 agreement; broker points to MT-101 and CU01 as follow-on candidates.
- companyMemento Medicines
U.S. developer that received global rights to Curacle’s MT-103 in a deal worth up to $1.08B, including an $8M upfront payment.
- brokerageShinhan Securities
Published a report identifying MT-101 and CU01 as potential follow-on licensing-out candidates for Curacle.
